NO20075368L - Antiinflammatoriske modaliteter - Google Patents

Antiinflammatoriske modaliteter

Info

Publication number
NO20075368L
NO20075368L NO20075368A NO20075368A NO20075368L NO 20075368 L NO20075368 L NO 20075368L NO 20075368 A NO20075368 A NO 20075368A NO 20075368 A NO20075368 A NO 20075368A NO 20075368 L NO20075368 L NO 20075368L
Authority
NO
Norway
Prior art keywords
inflammatory
inflammatory modalities
modalities
treatment
compounds
Prior art date
Application number
NO20075368A
Other languages
English (en)
Inventor
Alan James Husband
Catherine Walker
Michael John James
Original Assignee
Novogen Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005901475A external-priority patent/AU2005901475A0/en
Application filed by Novogen Res Pty Ltd filed Critical Novogen Res Pty Ltd
Publication of NO20075368L publication Critical patent/NO20075368L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Antiinflammatoriske modaliteter er beskrevet med referanse til valgte isoflavonoidforbindelser, sammensetninger inneholdende samme og anvendelsen av nevnte forbindelser og/eller sammensetninger ved behandlingen, særlig for behandling av inflammatoriske sykdommer og relaterte tilstander.
NO20075368A 2005-03-24 2007-10-19 Antiinflammatoriske modaliteter NO20075368L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2005901475A AU2005901475A0 (en) 2005-03-24 Isflavonoid dimers
US66860905P 2005-04-06 2005-04-06
AU2005905985A AU2005905985A0 (en) 2005-10-28 Pain and anti-inflammatory modalities
PCT/AU2006/000407 WO2006108212A1 (en) 2005-03-24 2006-03-24 Anti-inflammatory modalities

Publications (1)

Publication Number Publication Date
NO20075368L true NO20075368L (no) 2007-12-11

Family

ID=37023310

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20075367A NO20075367L (no) 2005-03-24 2007-10-19 Isoflavonoide dimerer
NO20075368A NO20075368L (no) 2005-03-24 2007-10-19 Antiinflammatoriske modaliteter

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20075367A NO20075367L (no) 2005-03-24 2007-10-19 Isoflavonoide dimerer

Country Status (14)

Country Link
US (3) US7700644B2 (no)
EP (3) EP1861090A4 (no)
JP (2) JP2008537545A (no)
CN (2) CN101203219B (no)
AT (1) ATE496921T1 (no)
AU (2) AU2006235194A1 (no)
CA (2) CA2602549A1 (no)
DE (1) DE602006019832D1 (no)
ES (1) ES2360130T3 (no)
IL (2) IL186218A0 (no)
MX (1) MX2007011493A (no)
NO (2) NO20075367L (no)
NZ (2) NZ561573A (no)
WO (2) WO2006099681A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029995A1 (ja) * 2008-09-11 2010-03-18 協和発酵キリン株式会社 疼痛治療剤
JP6115303B2 (ja) * 2012-05-18 2017-04-19 Jnc株式会社 隣接基としてカルボニル基を有するフェノール化合物およびその用途
KR101539180B1 (ko) * 2014-09-18 2015-07-24 성균관대학교산학협력단 플라보노이드계 화합물을 포함하는 림프부종의 예방 또는 치료용 조성물
KR101533197B1 (ko) * 2014-09-18 2015-07-02 성균관대학교산학협력단 부테인을 포함하는 부종의 예방 또는 치료용 조성물
DE112016001317T5 (de) 2015-03-20 2018-01-04 Stanford University Carbonat-unterstützte Carboxylierungsreaktion zur Synthese wertvoller organischer Verbindungen
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
EP3439642A4 (en) 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
RU2649119C1 (ru) * 2017-02-27 2018-03-29 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения язвенного колита
WO2019051548A1 (en) * 2017-09-15 2019-03-21 Norbio No. 2 Pty Ltd TREATMENT OF NEURO-INFLAMMATION
WO2020051644A1 (en) * 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
WO2021195698A1 (en) * 2020-03-30 2021-10-07 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN118373794B (zh) * 2024-04-17 2025-08-29 中国中医科学院中药研究所 一种异黄酮类化合物及其制备方法和在制药中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967362A (ja) * 1995-09-01 1997-03-11 Sankyo Co Ltd ５α−還元酵素阻害剤ビスイソフラボン類
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
DE69830929T2 (de) * 1997-11-11 2006-04-20 Nikken Chemicals Co., Ltd. N-hydroxyurea-derivat und dieses enthaltende pharmazeutische zusammensetzung
JP2002542187A (ja) * 1999-04-16 2002-12-10 アストラゼネカ・アクチエボラーグ エストロゲン−β受容体リガンド
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US20020016342A1 (en) * 2000-05-15 2002-02-07 Edward Scolnick Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
EP1368024A4 (en) * 2001-03-16 2009-03-18 Novogen Res Pty Ltd TREATMENT OF RESTENOSIS
CN1398586A (zh) * 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 新的取代庚酸衍生物治疗支气管哮喘和慢性阻塞性肺病
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
ATE532777T1 (de) * 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie

Also Published As

Publication number Publication date
NO20075367L (no) 2007-11-27
NZ561574A (en) 2010-03-26
WO2006099681A1 (en) 2006-09-28
IL186218A0 (en) 2008-01-20
EP1861402B1 (en) 2011-01-26
JP2008533177A (ja) 2008-08-21
EP1861090A1 (en) 2007-12-05
WO2006108212A1 (en) 2006-10-19
JP2008537545A (ja) 2008-09-18
CN101184756B (zh) 2011-08-03
HK1119557A1 (en) 2009-03-13
ES2360130T3 (es) 2011-06-01
US7700644B2 (en) 2010-04-20
US20080306140A1 (en) 2008-12-11
EP2526941A1 (en) 2012-11-28
NZ561573A (en) 2010-05-28
CN101203219A (zh) 2008-06-18
ATE496921T1 (de) 2011-02-15
DE602006019832D1 (de) 2011-03-10
CN101203219B (zh) 2011-06-15
EP1861402A4 (en) 2009-12-30
CN101184756A (zh) 2008-05-21
CA2602549A1 (en) 2006-10-19
US20090131513A1 (en) 2009-05-21
AU2006235194A1 (en) 2006-10-19
IL186217A0 (en) 2008-08-07
EP1861402A1 (en) 2007-12-05
CA2602541A1 (en) 2006-09-28
EP1861090A4 (en) 2010-01-06
AU2006227555A1 (en) 2006-09-28
MX2007011493A (es) 2008-04-14
US20120059176A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
NO20075367L (no) Isoflavonoide dimerer
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
CR20130455A (es) Composiciones para el tratamiento de tumores
IL249838A0 (en) Telomerase activating compounds for use in treating diseases related thereto
NO20081636L (no) FAP - inhibitorer
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
NO20071127L (no) Triazoloftalaziner
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
CL2008003602A1 (es) Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos.
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
EP2216043A4 (en) USE OF GSE24.2 INDUCTOR AGENTS FOR DEVELOPING PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH CELL SENESCENCE
DK1951274T3 (da) Parapoxvirusser i kombination med klasssiske cytotoksiske kemoterapeutiske midler som biokemoterapi til behandling af cancer
EA200701366A1 (ru) Кислородсодержащие аннелированные фенилпиперазин- и фенилдиазепанкарбоксамиды
ATE458738T1 (de) 2-alkoxy-3,4,5-trihydroxy-alkylamid- benzothiazepine, ihre herstellung und verwendung sowie diese enthaltende zusammensetzungen
DK1909800T3 (da) Acylglycerophospholipider til behandling af symptomer i forbindelse med cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application